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Abstract: Carbamoylation is an important risk factor for accelerated atherogenesis and mortality
in patients undergoing hemodialysis (HD). We intended to explore whether carbamoylation as
assessed by near-infrared (NIR) analysis of nail proteins is associated with (a) plasma concentrations
of representative uremic toxins and (b) mortality in HD patients. A total of 53 healthy volunteers
and 84 consecutive HD patients were enrolled in this cross-sectional cohort study. Standard
laboratory methods were used to measure routine parameters, whereas levels of uremic toxins were
determined using reversed-phase high-performance liquid chromatography (RP-HPLC). Spectra of
distal fingernail clippings were obtained using an Avantes NIR spectrometer and processed using
chemometric data analysis. The second derivative of the peak intensity at 1494 nm attributed to
N-H amide bands from NH2 of carbamoyl (-CONH2) groups was higher in HD patients than in
control subjects (p < 0.0001). Peak intensity levels were associated with age and plasma levels of
representative uremic toxins. Cox-regression analysis revealed a significant association with all-cause
mortality, even after adjustment for age. In conclusion, our data revealed that carbamoylation as
assessed by NIR analysis of nail proteins is associated with plasma concentrations of uremic toxins
and also with mortality in HD patients. Further research to explore whether it is a surrogate marker
or a hard indicator of mortality risk is warranted.
Keywords: carbamoylation; hemodialysis; keratins; mortality; nails; near-infrared spectroscopy;
uremia; uremic toxins
Key Contribution: Load of carbamoylated nail proteins as assessed by NIR spectroscopy is associated
with uremic toxins and is an important risk indicator for mortality in HD patients.
1. Introduction
Chronic kidney disease (CKD) is a global public health problem with a varying prevalence ranging
from 3–18%, depending on the region and population studied [1]. Patients with end-stage kidney
disease (ESKD) suffer from an annual mortality of 15–20%, which is largely due to cardiovascular
disease (CVD) [2]. Besides the traditional risk factors such as smoking, arterial hypertension and
Toxins 2020, 12, 83; doi:10.3390/toxins12020083 www.mdpi.com/journal/toxins
Toxins 2020, 12, 83 2 of 13
hypercholesterolemia [2], post-translational modifications (PTMs) of proteins are involved in the
pathogenesis of CVD and play an important role in the progression of CKD. PTMs are covalent changes
of proteins or peptides that are altered either by adding moieties to one or more amino acids or by
proteolytic cleavage [3]. In theory, all proteins are susceptible to PTMs in vivo. However, the potential
of each protein depends on several factors such as the accessibility and number of amino groups, as
well as the protein half-life [4]. PTMs such as carbamoylation, glycation, oxidation, glycoxidation and
methylation have different structural and functional effects [2].
The amounts of carbamoylated proteins are increased in hemodialysis (HD) patients when
compared with normal subjects due to their chronic hyperuremia state [3,4]. An enhanced degree
of carbamoylation has been identified as an important risk factor for accelerated atherogenesis and
mortality in patients undergoing HD [2,5]. Several biomarkers have been proposed to assess the extent
of protein carbamoylation in biological samples. Characteristic compounds such as homocitrulline often
require specialized analytical techniques such as liquid chromatography–tandem mass spectrometry
(LC-MS/MS) [6].
The human nail plate can be seen as a specialized keratinous skin appendage, which is in close
contact with the capillary bed of the fingers and toes. While a slower diffusion rate of molecules is
found in the nail matrix compared to serum, nail growth is a slow process (complete replacement takes
6–9 months on average) that allows the occurrence of chemical reactions between nail keratins and
small molecular mass compounds such as glucose and urea [7,8]. Nail keratins have the potential to
accumulate PTMs such as carbamoylation due to their high protein content (80% of total mass) and
long half-life (Figure 1) [2], which may eventually lead to changes in the near-infrared (NIR) spectrum
of the nail [7].
NIR spectroscopy is a simple, quick, cost-effective and noninvasive technique that uses the
780–2526 nm wavelength range of the electromagnetic spectrum. This region is mainly composed of
absorption bands related to overtones and combinations of fundamental vibrations of -CH, -NH, -OH
and -SH functional groups. NIR spectroscopy has major advantages over other analytical techniques.
It is able to provide information on the chemical composition of biological samples from one single
spectrum in a noninvasive and ultrafast way, without the need for sample preparation [9]. Therefore, we
intended to explore whether carbamoylation as assessed by NIR analysis of nail proteins is associated
with (a) plasma concentrations of uremic toxins and (b) mortality in HD patients.
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Figure 1. Carbamoylation is a nonenzymatic and irreversible post-translational modification during
which a carbamoyl group (-CONH2) is added to proteins, peptides and amino acids by reaction with
isocyanic acid, resulting in the formation of an irreversible covalent bond. Isocyanic acid originates
mainly (1) from the spontaneous decompostion of urea into ammonium and cyanate, a reactive ion
that is quickly converted to isocyanic acid, or (2) from myeloperoxidase (MPO)-catalyzed oxidation
of thiocyanate at sites of inflammation, including atherosclerotic plaques, or (3) from environmental
factors [2,10]. In chronic kidney disease, urea accumulates and elevates the concentration of isocyanic
acid. The latter rapidly reacts with the α-amino group of peptides, proteins (e.g., nail keratins) or
amino acids and with the ε-amino group of lysine, which results in the formation of homocitrulline
(ε-amino-carbamoyl-lysine) [2].
2. Results
2.1. The Peak Intensity at 1494 nm Is Significantly Higher in Hemodialysis Patients Versus Controls
A comparison of demographic characteristics, clinical characteristics and laboratory measurements
in controls and HD patients can be found in Table 1.
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Table 1. Demographic, clinical and laboratory measurements in healthy subjects and HD patients.
Variable Control (n = 53) HD (n = 84)
Demographic and Clinical
Age (yr) 34.8 (27.5–43.5) 73.7 (62.0–81.3)
Male/female ratio 18/35 52/32
Caucasian (%) 100 100
History of CVD (%) 0 59.5
Diabetes mellitus (%) 0 35.7
BMI (kg/m2) 23.2 (20.6–25.7) 26.1 (23.4–29.1)
Laboratory
Creatinine (mg/dL) 0.9 (0.8–1.0) 7.0 (5.0–8.8)
CRP (mg/L) 1.1 (0.7–2.8) 4.7 (1.9–10.8)
Total protein (g/L) 74.0 (69.9–81.5) 66.0 (62.5–69.6)
Urea (mg/dL) 26.7 (22.8–31.7) 99.0 (74.5–127.0)
IS total (mg/dL) 0.06 (0.04–0.08) 1.8 (1.0–2.6)
IS free (mg/dL) 0.001 (0.0005–0.001) 0.09 (0.05–0.2)
PCS total (mg/dL) 0.2 (0.1–0.3) 3.2 (2.0–4.2)
PCS free (mg/dL) 0.008 (0.003–0.01) 0.2 (0.1–0.3)
PCG total (mg/dL) 0.001 (0.001–0.001) 0.2 (0.1–0.4)
PCG free (mg/dL) 0.001 (0.001–0.001) 0.2 (0.08–0.4)
IAA total (mg/dL) 0.03 (0.02–0.03) 0.1 (0.1–0.2)
IAA free (mg/dL) 0.001 (0.001–0.002) 0.04 (0.03–0.06)
CMPF (mg/dL) 0.05 (0.01–0.1) 0.5 (0.3–0.9)
HA total (mg/dL) 0.07 (0.05–0.1) 2.7 (1.0–4.7)
HA free (mg/dL) 0.02 (0.006–0.04) 1.1 (0.5–2.6)
UA (mg/dL) 4.1 (3.4–5.3) 5.4 (4.8–6.4)
Abbreviations: BMI, body mass index; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid; CRP, C-reactive
protein; CVD, cardiovascular disease; HD, hemodialysis; HA, hippuric acid; IAA, indole acetic acid; IS, indoxyl
sulfate; PCG, p-cresylglucuronide; PCS, p-cresylsulfate; UA, uric acid; Yr, year. Data are presented as median
(interquartile range).
After using standard normal variate (SNV), Savitsky–Golay smoothing (SG, 7 points) and second
derivative conversion as preprocessing steps on the spectral range from 1038 to 2355 nm, preliminary
principal component analysis (PCA) results showed clear discrimination and clustering of healthy
subjects and HD patients. The same preprocessing steps were applied to the spectra of lysine and
homocitrulline powder (Figure 2A). Table 2 provides an overview of the characteristic spectral peaks
observed in the spectrum of homocitrulline together with associated functional groups, differences
with the spectrum of lysine, concordance with spectral changes observed in controls and HD patients
and the potential influence of diabetes mellitus (DM). From the 21 selected regions, 10 peaks showed
no significant differences between controls and HD patients. Eight regions showed spectral changes
in line with the spectra of homocitrulline and lysine and the differences observed between healthy
subjects and HD patients; three regions showed discordant results.
Figure 2B represents the median spectra of controls and HD patients with marking of concordant
regions, and Figure 3 provides a close-up on the latter. None of the eight regions were hampered by a
confounding effect of DM. Receiver operating characteristic (ROC) curve analysis was used to further
explore the diagnostic efficiency of the eight concordant spectral markers and yielded the best area
under the curves (AUCs) for the peak intensities at 1468 nm (AUC: 0.90, p < 0.0001), a region associated
with the N-H combination band from RCONH2 groups, and at 1494 nm (AUC: 0.82, p < 0.0001), a
region linked to N-H amide bands from NH2 groups. Comparison of age-matched controls did not
reveal significant differences between control samples stored for 438–897 days (n = 12, median value
intensity: 0.013, IQR: 0.011–0.01) and fresh obtained samples (n = 12, median value intensity 0.012,
IQR 0.011–0.012) for the peak intensity at 1494 nm (p = 0.13). However, in case of the peak intensity
at 1468 nm, significantly higher intensity values were found for the fresh obtained samples (median
value intensity: −0.0035, IQR: −0.0038 to −0.0021) compared to the stored samples (median value
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intensity: −0.0047, IQR: −0.0055 to −0.0034). Based on the latter, the spectral marker at 1494 nm was
selected as the most representative marker in the assessment of carbamoylated fingernail proteins and
used for further analysis. The procedure showed a good within-run precision (coefficient of variation
(CV) = 4.4%) for the peak intensity at 1494 nm.
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Figure 2. Spectral signature of carbamoylation. (A) Second derivative spectra of L-lysine (green line)
and L-homocitrulline (blue line) powder. Characteristic spectral peaks are indicated. (B) Second
derivative of the median spectra from controls (n = 53, green line) and hemodialysis patients (n = 84,
blue line). Concordant spectral changes with the differences observed in the spectra of lysine and
homocitrulline are highlighted (1494 nm region in red).
2.2. The Spectral Marker at 1494 nm Is Associated with Age and Uremic Toxins
Multiple linear regression analysis was run to reveal associations between the peak intensity at
1494 nm (milliunits) and age, presence of DM and uremic toxins. In separate models, age and several
uremic toxins (total indoxyl sulfate (IS), total p-cresylglucuronide (PCG), free PCG, free hippuric acid
(HA) and total HA) added significantly to the prediction. The presence of DM did not appear to be a
confounding factor. Table 3 provides an overview of the different multiple regression analysis models
with the peak intensity at 1494 nm as a dependent variable.
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Table 2. Overview of the characteristic spectral peaks observed in the spectrum of homocitrulline with
associated functional groups, differences with the spectrum of lysine, concordance with spectral changes
observed in controls (n = 53) and hemodialysis (HD, n = 84) patients and influence of diabetes mellitus (DM).
Wavelength
(nm)
Associated Functional
Groups
Homocit
vs. lys
Control
(Intensity)
HD
(Intensity) p In Line
Sign. Influence
DM (p)
1390 C-H bands increase −0.012 −0.011 <0.0001 yes No (0.24)
1468 CONH2 (N-Hcombination band) decrease −0.0044 −0.0062 <0.0001 yes No (0.42)
1494 N-H amide increase 0.012 0.014 <0.0001 yes No (0.90)
1532 N-H amide decrease 0.0097 0.0090 0.0001 yes Nearly sign.decrease (0.069)
1571 N-H amide increase 0.00034 −0.000043 0.0001 no No (0.72)
1610 C=O/N-H combination increase −0.00032 −0.0011 <0.0001 no No (0.91)
1655 C-H methyl increase −0.024 −0.026 0.0006 no Nearly sign.increase (0.073)
1693 CONH2 (N-H and C=O) decrease - - n.s. - -
1706 C-H methyl increase −0.0016 −0.00054 0.0003 yes No (0.80)
1744 CONH2 (C=O hydrogenbonded to N-H) decrease - - n.s. - -
1955 CONH2 (N-Hcombination band) decrease 0.0040 0.0029 <0.0001 yes No (0.83)
1981 CONH2 (N-H amide II) increase - - n.s. - -
2012 CONH2 (N-H/C-Ncombination band) - - - n.s. - -
2057 CONH2 (N-H/C=Oamide) increase - - n.s. - -
2069 N-H amide (N-Hdeformation) decrease - - n.s. - -
2095 N-H increase - - n.s. - -
2146 N-H/C-N/C=O increase −0.00076 0.00022 <0.0001 yes No (0.60)
2203 CONH2 (N-H and C=O) decrease 0.0048 0.0039 =0.010 yes No (0.39)
2222 N-H combination increase - - n.s. - -
2260 CONH2 (N-H and C=O) decrease - - n.s. - -
2291 CONH2 (C=O hydrogenbonded to N-H) increase - - n.s. - -
Abbreviations: homocit, homocitrulline; lys, lysine; nm, nanometer; n.s., nonsignificant; sign., significant. The
p-values represent the results of Mann–Whitney U tests.
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Figure 3. Close-up on the median second derivative spectra from controls (n = 53, green line) and
hemodialysis patients (n = 84, blue line) of the eight regions, characterized by changes in line with the
spectra of homocitrulline and lysine. (A) 1390 nm; (B) 1468 nm; (C) 1494 nm; (D) 1532 nm; (E) 1706 nm;
(F) 1955 nm; (G) 2146 nm; and (H) 2203 nm.
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Table 3. Multiple regression models with the peak intensity at 1494 nm (milliunits) as a dependent variable.
Model r2 (p)
Retained
Variables β (SE) p
Age, DM and urea 0.24 (<0.001) Age (yr) 0.038 (0.0060) <0.0001
Age, DM and IS total 0.27 (<0.001) Age (yr) 0.028 (0.0067) 0.0001
IS total (mg/dL) 0.34 (0.12) 0.0058
Age, DM and PCG total 0.26 (<0.001) Age (yr) 0.029 (0.0072) 0.0001
PCG total (mg/dL) 1.29 (0.58) 0.028
Age, DM and PCG free 0.26 (<0.001) Age (yr) 0.029 (0.0071) 0.0001
PCG free (mg/dL) 1.41 (0.63) 0.027
Age, DM and HA total 0.27 (<0.001) Age (yr) 0.029 (0.0067) <0.0001
HA total (mg/dL) 0.14 (0.050) 0.0063
Age, DM and HA free 0.26 (<0.001) Age (yr) 0.030 (0.21) <0.0001
HA free (mg/dL) 0.21 (0.082) 0.013
Abbrevations: DM, diabetes mellitus; HA, hippuric acid; IS, indoxyl sulfate; PCG, p-cresylglucuronide; SE, standard
error; Yr, year.
2.3. The Spectral Marker Has Prognostic Utility among Hemodialysis Patients
Univariate Cox regression analysis revealed that age (hazard ratio (HR) = 1.065, 95% confidence
interval (CI) = 1.028–1.10, p = 0.0005), history of CVD (HR = 2.81, 95% CI = 1.22–6.50, p = 0.016), free PCG
levels (HR = 11.67, 95% CI = 3.67–37.12, p < 0.0001), total PCG levels (HR = 8.97, 95% CI = 3.13–25.69,
p < 0.0001), free IS levels (HR = 133.00, 95% CI = 3.17–5584.22, p = 0.011), total HA levels (HR = 1.12,
95% CI = 1.01–1.24, p = 0.041) and free HA levels (HR = 1.20, 95% CI = 1.019–1.41, p = 0.030) were
significantly associated with the risk of death. The peak intensity at 1494 nm appeared to be significantly
higher among HD patients who died during the follow-up period (n = 31) than among HD patients
who survived (n = 53, p = 0.0007, Figure 4A,B).
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Figure 4. (A) Close-up on the second derivative spectra of the 1494 nm region in control subjects (n = 53,
green line), hemodialysis (HD) patients who survived (n = 53, blue line) and HD patients who died
during the 3-year follow-up period (n = 31, red line). (B) Box-and-whisker plots illustrating differences
in peak intensities between controls, HD patients who survived and HD patients who died during the
follow-up period. The p-values represent results obtained from Mann–Whitney U tests. Unadjusted (C)
and age-adjusted (D) cox-regression survival curves for increasing tertiles of the spectral marker at
1494 nm in the group of hemodialysis patients (n = 84).
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Table 4 shows the association of the spectral marker at 1494 nm with the risk of death in an
unadjusted model and an age-adjusted model. A significant association between the intensity at
1494 nm and all-cause mortality was found even after adjustment for age. Figure 4 shows the survival
plots of increasing tertiles of the spectral marker for the unadjusted model (Figure 4C) and the model
adjusted for age (Figure 4D).
Table 4. Unadjusted and age-adjusted Cox regression analysis for all-cause mortality with the intensity
at 1494 nm (milliunits) entered as a continuous variable in all hemodialysis patients (n = 84).
Models of Patient Survival
(Events n = 31) HR 95% CI p
Unadjusted Model
Intensity at 1494 nm (milliunits) 1.81 1.26–2.58 0.0012
Age-Adjusted Model
Intensity at 1494 nm (milliunits) 2.05 1.22–3.01 0.0001
Age (yr) 1.07 1.03–1.11 0.0002
Abbreviations: CI, confidence interval; HR, hazard ratio; yr, year.
3. Discussion
In the present paper, we identified for the first time several spectral features related to carbamoylation
in distal fingernail clippings of HD patients. The intensity at 1494 nm, attributed to N-H amide bands
from NH2 groups, was significantly associated with age and plasma levels of representative uremic
toxins. More important, this intensity was also significantly associated with mortality during the 3-year
follow-up period, even after adjusting for age. Our study demonstrates that measuring the load of
carbamoylated nail keratins through NIR analysis is a promising tool to identify HD patients at risk
due to uremic load. Further research to corroborate NIR as a hard indicator would yield an easy-to-use
indicator of uremic load that can be used to steer dialysis treatment.
Our data point out an association between concentrations of representative uremic toxins and
intensity of NIR analysis. Further research is needed to explore whether more intensive dialysis
regimens resulting in a decrease of uremic load would also result in changes in carbamoylation as
assessed by NIR. If this would be the case, NIR would be a good tool to assess the impact of changes
in dialysis regimen. The current method Kt/Vurea is recently progressively criticized as it is not
representative of uremic load and is also not associated with mortality [11,12]. Since our data revealed
that the spectral marker appeared to be an independent risk factor for mortality and is characterized
by significant associations with uremic toxins, we can hypothesize that lowering the level of uremic
toxins could lead to a decrease in its peak intensity and subsequently a lower mortality risk. Promising
for our hypothesis is that preliminary results obtained from HD patients before and after kidney
transplantation revealed a clear decrease of the spectral marker (data not shown). In contrast, in
a cohort of 21 patients on a stable HD regimen, and thus a stable uremic load, repetitive sampling
demonstrated no changes of spectral intensity over time (data not shown).
Direct NIR analysis of fingernails presents attractive features such as being ultrafast (<10 s analysis
time) and reagent-free. Moreover, handheld miniaturized NIR spectrometers offer great potential
for on-site monitoring [13,14]. Therefore, this approach is much easier than analytical techniques
classically used in the assessment of carbamoylated proteins such as LC-MS/MS [6]. Furthermore, in
contrast to serum or plasma, the nail matrix does not require important preanalytical precautions, as
even prolonged storage (4 ◦C) did not reveal significant differences for the peak intensity at 1494 nm.
In addition, nail keratins are hardly affected by intraindividual variability compared to other plasma
protein fractions. However, the methodology has to be standardized in the future to introduce this
analytical technique in clinical diagnostics. In addition, nail abnormalities such as trophic disturbances
and onychomycosis might be associated with spectral properties that interfere in our regions of interest.
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Since these abnormalities are much more common at the toenail level, fingernails are the preferred
matrix to avoid or minimize potential spectral interferences [14,15].
We did not perform LC-MS/MS, mostly considered the gold standard, to quantify the degree of
carbamoylation. However, while the LC-MS/MS technique has already been used for the quantification
of carbamoylated albumin and homocitrulline in serum or tissues [16,17], in fact no methods that
have been validated as gold standard are currently available for quantification of carbamoylated
nail keratins. Comparison of our NIR results with carbamoylation-derived products in serum is not
expected to provide essential information since fingernails are characterized by a much longer protein
half-life compared to cross-sectional samplings of blood markers. Nevertheless, our confidence that
the NIR spectra reveal carbamoylation is supported by the fact that the most discriminative regions
fall in biochemically very acceptable regions and that these regions are largely in concordance with
characteristic differences observed in the spectra of homocitrulline and lysine. Furthermore, the
NIR spectral intensity at 1494 nm is highly associated with age, whereas protein carbamoylation is a
hallmark of ageing [18,19]. Seemingly paradoxical, no significant association was found between the
spectral marker and levels of urea after adjustment for age. However, regarding the major differences
in half-life time between carbamoylated nail keratins and urea, a single snapshot measurement cannot
be perceived as being fully representative for the average urea levels observed during the duration of a
complete nail replacement (6–9 months). Furthermore, it has been widely accepted that serum urea
levels are poorly reflecting concentrations of other, more toxic, uremic retention products [12].
No significant confounding effect of the presence of DM (i.e., glycation) could be identified.
The latter is an important finding for several reasons. First of all, CKD and DM are diseases that
accelerate protein molecular ageing through carbamoylation and glycation reactions, respectively, on
the same protein amino groups, and, consequently, in vivo competition may arise. However, previous
research showed that carbamoylation exerts a more potent competitive effect on glycation than does
glycation on carbamylation [20]. Furthermore, due to the loss of renal function and inability of the
kidney to excrete advanced glycation end-product (AGE) precursors in HD patients, concentrations of
dicarbonyl metabolites are increased, which leads to an accumulation of AGEs [3]. However, it has
to be mentioned that next to carbamoylation and glycation, many other PTMs (e.g., oxidation) occur
during the biological life of proteins [21,22]. The latter is a plausible explanation for the fact that not all
spectral regions showed changes in line with the differences observed in the spectra of homocitrulline
and lysine.
4. Conclusions
In conclusion, load of carbamoylated nail proteins as assessed by NIR spectroscopy is associated
with uremic toxins and is an important risk indicator for mortality in HD patients. Further research to
explore whether it is a surrogate marker or a hard indicator of mortality risk is warranted. If this could
be demonstrated, the simple and highly economical character of the proposed method makes it a well
suited and innovative additional tool in the future management of HD patients.
5. Materials and Methods
5.1. Research Participants and Specimen Collection
For the cross-sectional cohort, a total of 53 healthy volunteers (male/female ratio: 18/35; median
age: 34.8 years) and 84 consecutive HD patients (male/female ratio: 52/32; median age: 73.7 years)
were enrolled in this study from December 2015 till September 2018. HD patients were recruited at
the Department of Nephrology of the Ghent University Hospital, Ghent, Belgium and were treated
with a regular 4-h conventional hemodialysis session (blood flow rate: 300–350 mL/min and dialysate
flow rate with an autoflow factor of 1.5) three times weekly. Distal fingernail specimens were obtained
with standard nail clippers and stored at 4 ◦C. The presence of nail polish was an exclusion criteria.
Blood samples (serum and plasma) were collected, centrifuged, aliquoted and stored at −80 ◦C until
Toxins 2020, 12, 83 10 of 13
analysis. The study was approved by the local Ethics Committee (Ethical approval recruitment of
control subjects: 2010/033; B67020107926, Ethical approval recruitment of dialysis patients: 2015/0932;
B670201525559). All participants signed a written informed consent.
5.2. Study Parameters
In ESKD patients, blood was taken before the start of a midweek HD session. In the overall
group, routine laboratory parameters were determined in serum using the Alinity c system (Abbott,
Chicago, IL, US). C-reactive protein was analyzed using a particle enhanced immunoturbidimetric
assay. Total protein, creatinine and urea were quantified using kinetic colorimetric assays based
on the biuret, Jaffé (compensated rate-blanked picrate assay) and Talke and Schubert’s methods,
respectively. As described earlier [23,24], seven uremic toxins were determined by reversed-phase high
performance liquid chromatography (RP-HPLC): the protein bound solutes indoxyl sulfate (IS, 213 Da),
p-cresylsulfate (PCS, 187 Da), p-cresylglucuronide (PCG, 284 Da), indole acetic acid (IAA, 175 Da),
3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF, 240 Da), hippuric acid (HA, 179 Da) and
the non-protein-bound uric acid (UA, 168 Da). Prior to analysis, samples were deproteinized by heat
denaturation (95 ◦C, 30 min) and afterwards placed on ice for 10 min. Afterwards, plasma samples were
centrifuged (7379 × g, 10 min) and filtered (3615 × g, 20 min, 21 ◦C) using a 30 kDa cut-off molecular
filter (Amicon Ultra 0.5 mL Filters, Merck KGaA, Darmstadt, Germany). To obtain free fractions, the
denaturation process was preceded by filtration (Centrifree filter device, Millipore Billerica, MA, USA).
While PCG and PCS (λexc = 265 nm, λem = 290 nm) and IAA and IS (λexc = 280 nm, λem = 340 nm)
were analyzed by fluorescence detection, HA and CMPF were determined by UV detection at 254 nm,
and UA at 300 nm. In the group of HD patients some additional markers were determined. White
blood cells, red blood cells, thrombocytes, hemoglobin and hematocrit were determined on a XE-5000
system (Sysmex, Bornbarch, Germany). Erythrocyte sedimentation rate was analyzed on a Starrsed RS
system (Sysmex, Bornbarch, Germany). While liver enzymes (aspartate aminotransferase and alanine
transaminase) were determined using a kinetic colorimetric assay on the Alinity c system, ferritin
concentrations were detected using a chemiluminescent microparticle immunoassay on an Alinity i
system (Abbott). In addition, comorbidity was assessed using the Stoke study scoring system (Davies
score) [25,26].
5.3. Near-Infrared Spectroscopy
Spectral data were obtained at ambient temperature using a NIR spectrometer (AvaSpecNIR256-2.5-HSC,
Avantes, Apeldoorn, the Netherlands) equipped with extended InGaAs array technology. Fingernails often
have a convex shape, which has consequences for measurements based on reflectance spectroscopy.
When a radiation beam hits a surface, it can be either transmitted, absorbed or reflected. The relative
amount of transmission and reflection depends largely on the refractive index of the sample, air and
angle of incidence. To obtain a sufficient amount of reflected beams onto the detector and consequently
sufficient signal intensity, the position of the radiation beam onto the convex nail sample has to be
carefully selected. In order to bypass this potential pitfall and exclude spectral variations caused by the
angle of incidence, an immobilized 50 mm integrating sphere was used (AvaSphere-50-LS-HAL-6-S1,
Avantes). An integrating sphere works as a uniform light collector independent of sample orientation
and allows analysis of extended sample areas [27]. Before nail analysis, visible dirt was removed
using a standard pincet. Ventral surfaces of the distal fingernail clippings were oriented towards the
integrating sphere and spectral data were recorded across the spectral range 1038–2354 nm at a spectral
resolution of 13 nm (128 co-added scans). All samples were analyzed in batch to minimize external
variabilities. In addition, NIR spectra of L-lysine powder (≥98%, Sigma-Aldrich, St. Louis, Missouri,
USA) and its carbamoylated analogue, i.e., L-homocitrulline (≥95%, Santa Cruz Biotechnology, Dallas,
TX, USA) were recorded. An in-depth comparison of the spectra was performed to identify spectral
changes related to the addition of a carbamoyl moiety (-CONH2) on protein or amino acid functional
groups. Since previous research of our group showed that glycated nail keratins are able to induce
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spectral changes in the NIR region [27], the potential influence of glycation in the zones of interest was
investigated by comparison of the peak intensities between HD patients with DM (n = 30) and HD
patients without DM (n = 54). To investigate a potential influence of storage time on spectral intensities,
age-matched control samples stored for 438–897 days at 4 ◦C (n = 12, median age 42.0, interquartile
range (IQR) 25.0–42.5) were compared with fresh obtained samples (n = 12, median age: 39.7 years,
IQR: 25.5–44.2 years).
5.4. Spectral Data Analysis
Spectral data analysis was carried out using SIMCA 15 (Umetrics, Umeå, Sweden). To standardize
spectroscopic signals and remove irrelevant scatter light, several preprocessing steps were employed [14].
NIR spectra were mean-centered, normalized using SNV method and converted to their derivatives
with a SG algorithm. We used SNV to remove additive baseline offset variations and multiplicative
scaling effects due to differences in sample density and sample-to-sample measurement variations,
and SG smoothing to minimize spectral noise. We used derivatives to enhance spectral discrimination
by highlighting small-scale differences between similar spectra, reducing baseline effects and causing
spectral resolution enhancement by resolving overlapping spectral bands [27,28]. The rate of change
of intensity with respect to wavelength (λ) was examined by the first derivative, whereas the second
derivative was used to assess alterations in the rate of change of intensity, an effective method for
removing sloping baselines [14,27]. After pretreatment of spectra, PCA was performed to sort spectra
and to get an impression of the complexity, heterogeneity and similarity of the dataset and thereby
unravelling spectral differences between healthy subjects and HD patients [13,29].
5.5. Statistical Analysis
Statistical data analysis was performed using MedCalc version 18.11 (MedCalc Software,
Mariakerke, Belgium). Normality of distributions was tested by the Kolmogorov–Smirnov test.
Values are expressed as median with IQR. Differences between two groups were assessed using the
Mann–Whitney U test. Multiple linear regression analysis was performed to unravel the association of
the peak intensity at 1494 nm with age, uremic toxins and the presence of DM (confouding factor).
To avoid collinearity bias, highly intercorrelated variables were not included in the same model.
Unadjusted and age-adjusted analyses of mortality were generated using Cox proportional-hazards
regression on the relative intensities as a continuous variable. A p value < 0.05 was considered a priori
to be statistically significant. To test the reproducibility of our method, fingernail clippings of three
randomly selected healthy subjects and three HD patients were analyzed 10 times to calculate the
within-run CV. ROC curve analysis was performed to unravel the discriminative potential of individual
spectral markers.
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